The Nantz National Alzheimer Center symposium will examine the striking advances made in the identification of plasma biomarkers for Alzheimer’s disease and related disorders. Plasma biomarkers will allow for the identification of people at risk and, likely, for measuring the speed of disease progression. Thus, they will be critical in clinical trials and for the application of new therapies.
Friday, February 18, 2022 at 8:30am to 5:00pm
Virtual Houston